Publikationen in Zusammenarbeit mit Forschern von Université de Sherbrooke (11)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

    JTO Clinical and Research Reports, Vol. 4, Núm. 1

2021

  1. Factors associated with fears due to COVID-19: A scleroderma patient-centered intervention network (SPIN) COVID-19 cohort study

    Journal of Psychosomatic Research, Vol. 140

2019

  1. New filovirus disease classification and nomenclature

    Nature Reviews Microbiology

2018

  1. Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes the TRIGR randomized clinical trial

    JAMA - Journal of the American Medical Association, Vol. 319, Núm. 1, pp. 38-48

  2. Randomized feasibility trial of the Scleroderma patient-centered intervention network hand exercise program (SPIN-HAND): Study protocol

    Journal of Scleroderma and Related Disorders, Vol. 3, Núm. 1, pp. 91-97

  3. The scleroderma patient-centered intervention network cohort: Baseline clinical features and comparison with other large scleroderma cohorts

    Rheumatology (United Kingdom), Vol. 57, Núm. 9, pp. 1623-1631

  4. Validation of the social interaction anxiety scale in scleroderma: A scleroderma patientcentered intervention network cohort study

    Journal of Scleroderma and Related Disorders, Vol. 3, Núm. 1, pp. 98-105

2016

  1. Examination of the association of sex and race/ethnicity with appearance concerns: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study

    Clinical and Experimental Rheumatology, Vol. 34, pp. 92-99

2007

  1. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trials

    Journal of the American Medical Association, Vol. 297, Núm. 12, pp. 1332-1343

2005

  1. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome study with Tolvaptan (EVEREST)

    Journal of Cardiac Failure, Vol. 11, Núm. 4, pp. 260-269